Source:http://linkedlifedata.com/resource/pubmed/id/12874087
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-10-3
|
pubmed:abstractText |
The influence of estrogen on the regulation of cardiovascular function remains a controversial and complex area of investigation. We assessed the effects of estrogen depletion in the congenic mRen(2). Lewis rat, established from the back-cross of the original (mRen2)-27 transgenic onto the Lewis inbred strain. Ovariectomy of heterozygous mRen(2). Lewis at 4 to 5 weeks resulted in a progressive increase in blood pressure compared with the sham surgery congenics at weeks 6 to 11. At 11 weeks, the ovariectomized mRen(2). Lewis (OVX) systolic blood pressure averaged 195+/-3.7 mm Hg versus 141+/-4.0 mm Hg for sham. Plasma Angiotensin (Ang) II, serum ACE activity, plasma renin concentration, as well as urinary excretion of Ang II, 8-isoprostane F2alpha, and endothelin-1 were elevated; however, renal mRNA levels of eNOS were suppressed after ovariectomy. Estrogen replacement reduced blood pressure below both the sham and OVX by 11 weeks (125+/-2.9 mm Hg, n=7, P<0.01 versus OVX and sham). Moreover, the AT1 receptor antagonist olmesartan (CS866; week 12 to 16) essentially normalized blood pressure to 113+/-5.4 mm Hg (n=6, P<0.01 versus OVX and sham). The attenuation of the hypertension was still evident 7 weeks after complete withdrawal of treatment (124+/-4.1 mm Hg at week 23). In summary, the OVX mRen.2. Lewis exhibited a rapid and sustained increase in blood pressure. Estrogen or olmesartan lowered pressure by a similar extent. We conclude that the ovary exerts considerable influence on the regulation of the blood pressure in the mRen2. Lewis strain, possibly by limiting activation of the renin-angiotensin system.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/8-epi-prostaglandin F2alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprost,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/F2-Isoprostanes,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Ren2 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Renin,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/olmesartan medoxomil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1524-4563
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
781-6
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12874087-Angiotensin Receptor Antagonists,
pubmed-meshheading:12874087-Animals,
pubmed-meshheading:12874087-Animals, Congenic,
pubmed-meshheading:12874087-Blood Pressure,
pubmed-meshheading:12874087-Dinoprost,
pubmed-meshheading:12874087-Disease Progression,
pubmed-meshheading:12874087-Endothelin-1,
pubmed-meshheading:12874087-Estradiol,
pubmed-meshheading:12874087-F2-Isoprostanes,
pubmed-meshheading:12874087-Female,
pubmed-meshheading:12874087-Hypertension,
pubmed-meshheading:12874087-Imidazoles,
pubmed-meshheading:12874087-Male,
pubmed-meshheading:12874087-Mice,
pubmed-meshheading:12874087-Ovariectomy,
pubmed-meshheading:12874087-Rats,
pubmed-meshheading:12874087-Rats, Inbred Lew,
pubmed-meshheading:12874087-Receptor, Angiotensin, Type 1,
pubmed-meshheading:12874087-Renin,
pubmed-meshheading:12874087-Renin-Angiotensin System,
pubmed-meshheading:12874087-Tetrazoles
|
pubmed:year |
2003
|
pubmed:articleTitle |
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.
|
pubmed:affiliation |
Hypertension and Vascular Disease Center, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-1095, USA. mchappel@wfubmc.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|